Feb. 22–24, 2021 • VIRTUAL ProgramDownload program flyerMeeting Code of ConductEvent site is now live! Registered attendees, click here to access the event. Use the access information you received in the recent "Know Before You Go" email. If you did not receive access information via email, please let us know at firstname.lastname@example.org.
The Society for Immunotherapy of Cancer (SITC) is pleased to host its third annual Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, which will be held virtually on Feb. 22–24, 2021. Taught by leading experts in the field, this program provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.The program is tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings as well as those new to the field. The curriculum covers the fundamentals of cancer immunotherapy and features separate tracks, including clinical and research, allowing participants to tailor their experience by selecting the educational path most relevant to their learning goals.
To support young investigators and clinicians interested in attending the Cancer Immunotherapy Winter School, SITC accepted applications for travel awards, which will supplement costs for those honored to attend. Those honored with a 2021 Cancer Immunotherapy Winter School travel award include:Xue Bai, MD — Peking University Cancer HospitalAmy Cunningham–Bussel, MD, PhD — Brigham and Women's HospitalSapana Kadel, PhD — Dana-Farber Cancer InstituteBarbara Ma, MD — New York Presbyterian / Weill CornelFilippo Pederzoli, MD — IRCCS Ospedale San Raffaele
SITC's Cancer Immunotherapy Winter School is supported, in part, by independent medical educational grants from AbbVie Inc., AstraZeneca Pharmaceuticals LP and Exelixis, Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com